| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 2 securities · may seek to influence control | ||||||
|
Mobia Medical, Inc.
13D
MOBI · 83084G109
|
9.8% |
5/13/2026
Event 5/11/2026
|
||||
| Longitude Capital Partners V, LLC | 6.3% | |||||
| Longitude Venture Partners V, L.P. | 6.3% | |||||
| Longitude 103.8 East Partners, LLC | 3.5% | |||||
| Longitude 103.8 East, L.P. | 3.5% | |||||
| Patrick G. Enright | 9.8% | |||||
| Juliet Tammenoms Bakker | 9.8% | |||||
|
Veradermics, Incorporated
13D/A
MANE · 922967104
|
11.3% |
5/5/2026
Event 5/1/2026
|
||||
| Longitude Capital Partners V, LLC | 6.3% | |||||
| Longitude Venture Partners V, L.P. | 6.3% | |||||
| Longitude 103.8 East Partners, LLC | 5.0% | |||||
| Longitude 103.8 East, L.P. | 5.0% | |||||
| Patrick G. Enright | 11.3% | |||||
| Juliet Tammenoms Bakker | 11.3% | |||||
| Schedule 13G · 2 securities · passive | ||||||
|
Entera Bio Ltd.
13G
ENTX · M40527109
|
4.6% |
8/4/2026
Event 7/28/2026
|
||||
| Longitude Capital Partners V, LLC | 4.6% | |||||
| Longitude Venture Partners V, L.P. | 4.6% | |||||
| Patrick G. Enright | 4.6% | |||||
| Juliet Tammenoms Bakker | 4.6% | |||||
|
CytomX Therapeutics, Inc.
13G/A
CTMX · 23284F105
|
7.0% |
5/15/2026
Event 3/31/2026
|
||||
| Longitude Capital Partners V, LLC | 5.7% | |||||
| Longitude Venture Partners V, L.P. | 5.7% | |||||
| Longitude 103.8 East Partners, LLC | 1.3% | |||||
| Longitude 103.8 East, L.P. | 1.3% | |||||
| Patrick G. Enright | 7.0% | |||||
| Juliet Tammenoms Bakker | 7.0% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.